MedTrace Logo

Omacor and Placebo in Carotid Plaque Stability

NCT00294216 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2006-02-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of intake of Omacor (Omega-3-acid ethyl ester 90) 2g/day on specified parameters related to the stability of carotid plaque in patients awaiting endarterectomy.

Conditions

Interventions

DRUG

Omega-3-acid ethyl ester 90 (n-3 PUFA)

Sponsors & Collaborators

  • Pronova BioPharma

    lead INDUSTRY

Principal Investigators

  • Philip C. Calder, PhD · University of Southampton, School of Medicine, Institute of Human Nutrition

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2005-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294216 on ClinicalTrials.gov